PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts

Am J Physiol Cell Physiol. 2002 Jan;282(1):C125-33. doi: 10.1152/ajpcell.2002.282.1.C125.

Abstract

This work demonstrated the constitutive expression of peroxisome proliferator-activated receptor (PPAR)-gamma and PPAR-alpha in rat synovial fibroblasts at both mRNA and protein levels. A decrease in PPAR-gamma expression induced by 10 microg/ml lipopolysaccharide (LPS) was observed, whereas PPAR-alpha mRNA expression was not modified. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) dose-dependently decreased LPS-induced cyclooxygenase (COX)-2 (-80%) and inducible nitric oxide synthase (iNOS) mRNA expression (-80%), whereas troglitazone (10 microM) only inhibited iNOS mRNA expression (-50%). 15d-PGJ(2) decreased LPS-induced interleukin (IL)-1 beta (-25%) and tumor necrosis factor (TNF)-alpha (-40%) expression. Interestingly, troglitazone strongly decreased TNF-alpha expression (-50%) but had no significant effect on IL-1 beta expression. 15d-PGJ(2) was able to inhibit DNA-binding activity of both nuclear factor (NF)-kappa B and AP-1. Troglitazone had no effect on NF-kappa B activation and was shown to increase LPS-induced AP-1 activation. 15d-PGJ(2) and troglitazone modulated the expression of LPS-induced iNOS, COX-2, and proinflammatory cytokines differently. Indeed, troglitazone seems to specifically target TNF-alpha and iNOS pathways. These results offer new insights in regard to the anti-inflammatory potential of the PPAR-gamma ligands and underline different mechanisms of action of 15d-PGJ(2) and troglitazone in synovial fibroblasts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Cells, Cultured
  • Chromans / pharmacology
  • Cyclooxygenase 2
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Gene Expression / drug effects
  • Gene Expression / physiology
  • Interleukin-1 / genetics
  • Isoenzymes / genetics
  • Ligands
  • Lipopolysaccharides / pharmacology*
  • Male
  • NF-kappa B / antagonists & inhibitors
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase Type II
  • Prostaglandin D2 / analogs & derivatives*
  • Prostaglandin D2 / pharmacology
  • Prostaglandin-Endoperoxide Synthases / genetics
  • RNA, Messenger / analysis
  • Rats
  • Rats, Wistar
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Synovial Membrane / cytology*
  • Synovial Membrane / immunology
  • Thiazoles / pharmacology
  • Thiazolidinediones*
  • Transcription Factor AP-1 / antagonists & inhibitors
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Troglitazone
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Antineoplastic Agents
  • Chromans
  • Interleukin-1
  • Isoenzymes
  • Ligands
  • Lipopolysaccharides
  • NF-kappa B
  • RNA, Messenger
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factor AP-1
  • Transcription Factors
  • Tumor Necrosis Factor-alpha
  • 9-deoxy-delta-9-prostaglandin D2
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Troglitazone
  • Prostaglandin D2